OR WAIT null SECS
Catalent is investing nearly $35 million in a major expansion of its controlled-release drug manufacturing facility in Winchester, Kentucky.
Catalent is investing nearly $35 million in a major expansion of its controlled-release drug manufacturing facility in Winchester, Kentucky. Construction started on June 12, 2013, with the expansion expected to be completed by October 2014. The company’s 100,000 square-foot facility will be expanded by almost 80,000 square feet and will add as many as 90 new employees at the expanded site.
“The expanded Winchester facility will provide our customers with enhanced access to custom equipment capabilities and our market-leading controlled release solutions and technologies,” said Steve Havel, General Manager of Catalent’s Winchester facility, in a press statement.
The Winchester facility, opened in 1992, is one of the company’s main sites for advanced oral controlled-release drug formulation and manufacturing and this expansion follows several investments Catalent has made in advanced delivery technologies globally.
“As with Winchester, Catalent continues to invest to meet the most critical needs of the industry, including recently announced inhalation facility expansion in North Carolina, our recently completed biologics expansion in Wisconsin, and our two new ventures in China, which will focus on softgel technologies and clinical trial supplies.”